21 results
8-K
EX-2.1
MIRM
Mirum Pharmaceuticals Inc
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
Business has sent any Hazardous Substances or waste for storage, handling, disposal or treatment, or (iii) at any other location with respect to which … and polyfluoroalkyl substances, asbestos and radon; (E) any other pollutant or contaminant; and (F) any substance, material or waste regulated by any
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
29 Sep 21
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
4:42pm
The accumulation of bile acids prevents the liver from working properly to eliminate waste from the bloodstream and, according to recent reports, 60% to 75
8-K
EX-99.1
gju6fq8leaoto954m
10 Dec 20
Revenue Interest Purchase Agreement
9:11am
10-K
zu8ahszwgr
12 Mar 20
Annual report
4:16pm
424B4
kb78sg35bt1g
9 Jan 20
Prospectus supplement with pricing info
5:11pm
DRS
6g2yp0u0
27 Dec 19
Draft registration statement
12:00am
DRS
EX-10.15
dwmlve3ff7k q6d8
27 Dec 19
Draft registration statement
12:00am
424B4
0hcee504dcghgt8
18 Jul 19
Prospectus supplement with pricing info
4:04pm
S-1
EX-10.14
qs14xuy 6lur
21 Jun 19
IPO registration
3:24pm
S-1
kdxwkks4wu5pwcgocw
21 Jun 19
IPO registration
3:24pm
DRS/A
59fdc6enp5a4
24 May 19
Draft registration statement (amended)
12:00am
DRS
EX-10.14
lpmtx1er g2
18 Apr 19
Draft registration statement
12:00am